Results 11 to 20 of about 211,312 (294)

Considerations of Antibody Geometric Constraints on NK Cell Antibody Dependent Cellular Cytotoxicity

Frontiers in Immunology, 2020
It has been well-established that antibody isotype, glycosylation, and epitope all play roles in the process of antibody dependent cellular cytotoxicity (ADCC).
Charles D. Murin
doaj   +1 more source

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma

Frontiers in Immunology, 2023
BackgroundDespite recent advances in the treatment of aggressive lymphomas, a significant fraction of patients still succumbs to their disease. Thus, novel therapies are urgently needed. As the anti-CD20 antibody rituximab and the CD19-targeting antibody
Maria Patra-Kneuer, Gaomei Chang, Wendan Xu, Christian Augsberger, Michael Grau, Myroslav Zapukhlyak, Kristina Ilieva, Karin Landgraf, Doris Mangelberger-Eberl, Kasra Yousefi, Philipp Berning, Katrin S. Kurz, German Ott, Pavel Klener, Pavel Klener, Cyrus Khandanpour, Cyrus Khandanpour, Pedro Horna, Jürgen Schanzer, Stefan Steidl, Jan Endell, Christina Heitmüller, Georg Lenz   +22 more
doaj   +1 more source

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

Haematologica, 2011
Background In our efforts to develop novel effective treatment regimens for multiple myeloma we evaluated the potential benefits of combining the immunomodulatory drug lenalidomide with daratumumab.
Michael. S. van der Veer, Michel de Weers, Berris van Kessel, Joost M. Bakker, Shulamiet Wittebol, Paul W.H.I. Parren, Henk M. Lokhorst, Tuna Mutis   +7 more
doaj   +1 more source

From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement

Frontiers in Immunology, 2022
Antibody-dependent cell-mediated cytotoxicity (ADCC) is a potent cytotoxic mechanism that is mainly mediated in humans by natural killer (NK) cells. ADCC mediates the clinical benefit of several widely used cytolytic monoclonal antibodies (mAbs), and ...
Loïs Coënon, Loïs Coënon, Martin Villalba, Martin Villalba   +3 more
doaj   +1 more source

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

Journal of Hematology & Oncology, 2016
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including ...
Larysa Sanchez, Yucai Wang, David S. Siegel, Michael L. Wang   +3 more
doaj   +1 more source

Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells

Frontiers in Immunology, 2020
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM).
Chen Zhu, Zhili Song, Anlai Wang, Srimathi Srinivasan, Guang Yang, Rita Greco, Joachim Theilhaber, Elvis Shehu, Lan Wu, Zhi-Yong Yang, Wilfried Passe-Coutrin, Alain Fournier, Yu-Tzu Tai, Kenneth C. Anderson, Dmitri Wiederschain, Keith Bahjat, Francisco J. Adrián, Marielle Chiron   +17 more
doaj   +1 more source

Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines

BMC Cancer, 2012
Background Despite strong efforts to improve clinical outcome of ovarian cancer patients by conventional and targeted immuno-based therapies, the prognosis of advanced ovarian cancer is still poor.
Gottschalk Nina, Lang Stephan, Kimmig Rainer, Singh Mahavir, Brandau Sven   +4 more
doaj   +1 more source

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering

Haematologica, 2019
CD20 monoclonal antibody therapies have significantly improved the outlook for patients with B-cell malignancies. However, many patients acquire resistance, demonstrating the need for new and improved drugs.
Simone C. Oostindie, Hilma J. van der Horst, Margaret A. Lindorfer, Erika M. Cook, Jillian C. Tupitza, Clive S. Zent, Richard Burack, Karl R. VanDerMeid, Kristin Strumane, Martine E. D. Chamuleau, Tuna Mutis, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Frank J. Beurskens, Paul W. H. I. Parren, Ronald P. Taylor   +16 more
doaj   +1 more source

Comparative efficiency of HIV-1-infected T cell killing by NK cells, monocytes and neutrophils.

PLoS ONE, 2013
HIV-1 infected cells are eliminated in infected individuals by a variety of cellular mechanisms, the best characterized of which are cytotoxic T cell and NK cell-mediated killing.
Adjoa Smalls-Mantey, Mark Connors, Quentin J Sattentau   +2 more
doaj   +1 more source

Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis

Cell Reports, 2018
Summary: Destruction of cancer cells by therapeutic antibodies occurs, at least in part, through antibody-dependent cellular cytotoxicity (ADCC), and this can be mediated by various Fc-receptor-expressing immune cells, including neutrophils. However, the
Hanke L. Matlung, Liane Babes, Xi Wen Zhao, Michel van Houdt, Louise W. Treffers, Dieke J. van Rees, Katka Franke, Karin Schornagel, Paul Verkuijlen, Hans Janssen, Pasi Halonen, Cor Lieftink, Roderick L. Beijersbergen, Jeanette H.W. Leusen, Jaap J. Boelens, Ingrid Kuhnle, Jutte van der Werff Ten Bosch, Karl Seeger, Sergio Rutella, Daria Pagliara, Takashi Matozaki, Eiji Suzuki, Catharina Willemien Menke-van der Houven van Oordt, Robin van Bruggen, Dirk Roos, Rene A.W. van Lier, Taco W. Kuijpers, Paul Kubes, Timo K. van den Berg   +28 more
doaj   +1 more source